David Gossage

3.2k total citations · 2 hit papers
29 papers, 2.4k citations indexed

About

David Gossage is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, David Gossage has authored 29 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Physiology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in David Gossage's work include Asthma and respiratory diseases (12 papers), Respiratory and Cough-Related Research (7 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers). David Gossage is often cited by papers focused on Asthma and respiratory diseases (12 papers), Respiratory and Cough-Related Research (7 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers). David Gossage collaborates with scholars based in United States, Australia and Spain. David Gossage's co-authors include Néstor A. Molfino, Roland Kolbeck, Deepak Khatry, William W. Busse, Trung N. Tran, Gregory P. Geba, Yanping Wu, Sally E. Wenzel, Christine K. Ward and Rohit Katial and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and PLoS ONE.

In The Last Decade

David Gossage

29 papers receiving 2.4k citations

Hit Papers

Effects of benralizumab on airway eosinophils in asthmati... 2013 2026 2017 2021 2013 2014 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
    2013 370 citations Michel Laviolette, David Gossage et al. Journal of Allergy and Clinical Immunology profile →
  2. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
    2014 362 citations Mario Castro, Sally E. Wenzel et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Gossage United States 17 1.7k 1.3k 605 567 456 29 2.4k
Tomomitsu Hirota Japan 30 1.1k 0.7× 417 0.3× 306 0.5× 903 1.6× 599 1.3× 74 2.4k
Cheryl Protheroe United States 25 1.1k 0.7× 390 0.3× 1.1k 1.8× 1.2k 2.1× 291 0.6× 33 2.6k
Shin‐ichiro Kagami Japan 27 870 0.5× 270 0.2× 251 0.4× 2.0k 3.5× 260 0.6× 56 2.9k
Charlotte P. Peters Netherlands 14 532 0.3× 89 0.1× 1.6k 2.6× 2.3k 4.1× 144 0.3× 23 2.8k
PF Weller United States 12 254 0.1× 323 0.2× 521 0.9× 449 0.8× 92 0.2× 21 1.3k
Jochem H. Bernink Netherlands 21 448 0.3× 98 0.1× 2.0k 3.4× 3.3k 5.9× 128 0.3× 25 3.7k
Sabine Charron France 14 177 0.1× 491 0.4× 149 0.2× 628 1.1× 38 0.1× 19 1.5k
Susumu Yasuoka Japan 20 186 0.1× 304 0.2× 83 0.1× 220 0.4× 90 0.2× 55 1.1k
Ya‐Hui Chuang Taiwan 29 175 0.1× 451 0.3× 486 0.8× 905 1.6× 87 0.2× 77 2.6k
Manuela Capone Italy 22 266 0.2× 106 0.1× 161 0.3× 1.7k 3.1× 101 0.2× 45 2.4k

Countries citing papers authored by David Gossage

Since Specialization
Citations

This map shows the geographic impact of David Gossage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Gossage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Gossage more than expected).

Fields of papers citing papers by David Gossage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Gossage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Gossage. The network helps show where David Gossage may publish in the future.

Co-authorship network of co-authors of David Gossage

This figure shows the co-authorship network connecting the top 25 collaborators of David Gossage. A scholar is included among the top collaborators of David Gossage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Gossage. David Gossage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ordoñez, Alvaro A., Supriya Pokkali, Sun-Hwa Kim, et al.. (2018). Adjunct antibody administration with standard treatment reduces relapse rates in a murine tuberculosis model of necrotic granulomas. PLoS ONE. 13(5). e0197474–e0197474. 20 indexed citations
2.
Gossage, David, Hao Zheng, Yan Xin, et al.. (2017). Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis. Clinical Therapeutics. 40(1). 156–165.e5. 43 indexed citations
3.
Zeiger, Robert S., Michael Schatz, Qiaowu Li, et al.. (2015). The association of blood eosinophil counts to future asthma exacerbations in children with persistent asthma. The Journal of Allergy and Clinical Immunology In Practice. 3(2). 283–287.e4. 28 indexed citations
4.
Khatry, Deepak, David Gossage, Gregory P. Geba, et al.. (2015). Discriminating sputum-eosinophilic asthma: Accuracy of cutoffs in blood eosinophil measurements versus a composite index, ELEN. Journal of Allergy and Clinical Immunology. 136(3). 812–814.e2. 23 indexed citations
5.
Barker, Alan F., Anne E. O’Donnell, Patrick A. Flume, et al.. (2014). Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. The Lancet Respiratory Medicine. 2(9). 738–749. 153 indexed citations
6.
Zeiger, Robert S., Michael Schatz, Qiaowu Li, et al.. (2014). High Blood Eosinophil Count Is a Risk Factor for Future Asthma Exacerbations in Adult Persistent Asthma. The Journal of Allergy and Clinical Immunology In Practice. 2(6). 741–750.e4. 188 indexed citations
7.
Tran, Trung N., et al.. (2014). High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Annals of Allergy Asthma & Immunology. 113(1). 19–24. 137 indexed citations
8.
Castro, Mario, Sally E. Wenzel, Eugene R. Bleecker, et al.. (2014). Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. The Lancet Respiratory Medicine. 2(11). 879–890. 362 indexed citations breakdown →
9.
Barker, Alan R., Anne O’Donnell, Philip J. Thompson, et al.. (2013). Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB). European Respiratory Journal. 42(Suppl 57). P4136–P4136. 10 indexed citations
10.
Gold, David, Michelle Dawson, Harry Yang, Joseph M. Parker, & David Gossage. (2013). Clinical Trial Simulation To Assist In COPD Trial Planning And Design With A Biomarker-Based Diagnostic: When To Pull The Trigger?. COPD Journal of Chronic Obstructive Pulmonary Disease. 11(2). 226–235. 2 indexed citations
11.
Laviolette, Michel, David Gossage, Gail M. Gauvreau, et al.. (2013). Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. Journal of Allergy and Clinical Immunology. 132(5). 1086–1096.e5. 370 indexed citations breakdown →
12.
Gossage, David, Michel Laviolette, Gail M. Gauvreau, et al.. (2012). Depletion Of Airway Eosinophils By Benralizumab An Anti-IL5 Receptor Alpha Monoclonal Antibody. A3961–A3961. 3 indexed citations
13.
Busse, William W., Rohit Katial, David Gossage, et al.. (2010). Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma. Journal of Allergy and Clinical Immunology. 125(6). 1237–1244.e2. 217 indexed citations
14.
Schaffer, Frederick M., Isabel Virella‐Lowell, Richard A. Gatti, & David Gossage. (2007). Ataxia-Telangiectasia, Associated with a Rare 1339C>T ATM mutation, presenting in infancy with Pneumocystis carinii pneumonia, and an elevated serum IgM.. The Journal of Immunology. 178. 2 indexed citations
15.
Schaffer, Frederick M., Isabel Virella‐Lowell, Richard A. Gatti, & David Gossage. (2007). Ataxia-Telangiectasia, Associated with a Rare 1339C>T ATM mutation, presenting in infancy with Pneumocystis carinii pneumonia, and an elevated serum IgM. (35.11). The Journal of Immunology. 178(1_Supplement). S3–S3. 1 indexed citations
16.
Heidemann, David G., et al.. (2000). Delayed Onset and Recurrent Alcaligenes xylosoxidans Keratitis. Cornea. 19(2). 243–245. 21 indexed citations
17.
Brickner, Anthony G., David Gossage, Mary R. Dusing, & Dan A. Wiginton. (1995). Identification of a murine homolog of the human adenosine deaminase thymic enhancer. Gene. 167(1-2). 261–266. 14 indexed citations
18.
Washington, Kay, David Gossage, & Marcia R. Gottfried. (1994). Pathology of the pancreas in severe combined immunodeficiency and DiGeorge syndrome: Acute graft-versus-host disease and unusual viral infections. Human Pathology. 25(9). 908–914. 13 indexed citations
19.
Washington, Kay, David Gossage, & Marcia R. Gottfried. (1993). Pathology of the Liver in Severe Combined Immunodeficiency and Digeorge Syndrome. Pediatric Pathology. 13(4). 485–504. 11 indexed citations
20.
Raghow, Rajendra, David Gossage, & A H Kang. (1986). Pretranslational regulation of type I collagen, fibronectin, and a 50-kilodalton noncollagenous extracellular protein by dexamethasone in rat fibroblasts.. Journal of Biological Chemistry. 261(10). 4677–4684. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomomitsu Hirota Breakdown of academic impact, for papers by Cheryl Protheroe Breakdown of academic impact, for papers by Shin‐ichiro Kagami Breakdown of academic impact, for papers by Charlotte P. Peters Breakdown of academic impact, for papers by PF Weller Breakdown of academic impact, for papers by Jochem H. Bernink Breakdown of academic impact, for papers by Sabine Charron Breakdown of academic impact, for papers by Susumu Yasuoka Breakdown of academic impact, for papers by Ya‐Hui Chuang Breakdown of academic impact, for papers by Manuela Capone
Rankless by CCL
2026